Influence of Estrogen Treatment on ESR1 + and ESR1 - Cells in ER + Breast Cancer: Insights from Single-Cell Analysis of Patient-Derived Xenograft Models.

A 100% ER positivity is not required for an endocrine therapy response. Furthermore, while estrogen typically promotes the progression of hormone-dependent breast cancer via the activation of estrogen receptor (ER)-α, estrogen-induced tumor suppression in ER + breast cancer has been clinically observed. With the success in establishing estrogen-stimulated (SC31) and estrogen-suppressed (GS3) patient-derived xenograft (PDX) models, single-cell RNA sequencing analysis was performed to determine the impact of estrogen on ESR1 + and ESR1 - tumor cells. We found that 17β-estradiol (E2)-induced suppression of GS3 transpired through wild-type and unamplified ERα. E2 upregulated the expression of estrogen-dependent genes in both SC31 and GS3; however, E2 induced cell cycle advance in SC31, while it resulted in cell cycle arrest in GS3. Importantly, these gene expression changes occurred in both ESR1 + and ESR1 - cells within the same breast tumors, demonstrating for the first time a differential effect of estrogen on ESR1 - cells. E2 also upregulated a tumor-suppressor gene, IL-24 , in GS3. The apoptosis gene set was upregulated and the G2M checkpoint gene set was downregulated in most IL-24 + cells after E2 treatment. In summary, estrogen affected pathologically defined ER + tumors differently, influencing both ESR1 + and ESR1 - cells. Our results also suggest IL-24 to be a potential marker of estrogen-suppressed tumors.